Insider buying last 90 days
No open-market insider purchases were filed for CLDX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CLDX insider filing, plotted on the chart in Gekko.Open CLDX in Gekko
NASDAQ: CLDX
Celldex Therapeutics (CLDX) Stock Analysis & Forecast
Oct 12 close
$29.43−0.46 (−1.5%)
Gekko Brief
AI summaryOct 12 closeCelldex Therapeutics this week centered on positive Phase 3 results for barzolvolimab, with two studies, EMBARQ-CSU1 and EMBARQ-CSU2, meeting primary and key secondary endpoints in chronic spontaneous urticaria and complete response rates reaching up to 54.0 percent in treated groups compared to placebo. HC Wainwright reaffirmed a Buy rating with a $64.00 price target following the data. Separately, FMR LLC and Abigail P. Johnson disclosed a 10.7% beneficial ownership stake as of September 30, 2026, and a shareholder investigation was announced by a law firm.
The stock closed at $29.43, down 1.5%, sitting below both its 50-day average of $37.53 and its 200-day average of $32.46, with one-month and three-month returns of -20.2% and -22.9% respectively, against a 52-week range of $22.10 to $45.14. The GekkoIndex reads 69.4, placing it in the Accumulation zone, and the price sits 32.1% below the Gekko Fair Value of $43.35.
Celldex is scheduled to report earnings on 9 November 2026, 28 days away and inside a typical 20-trading-day holding window, with prior quarters showing 5 beats out of 8 and an average absolute reaction of 4.8%. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality over the next 20 trading days has averaged -1.8% across 5 years, rising in 2 of them. Analyst consensus from 12 firms shows 11 Buy and 1 Hold ratings, with a consensus target of $63.07.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Celldex Therapeutics price vs fair value
Close $29.43200-day averageGekko Fair Value $43.35
Celldex Therapeutics quick facts
- Market cap
- $1.96B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$4.35
- Revenue, TTM
- $158K
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.90
- Volume
- 596,401 avg 2.35M
- 1-year return
- +6.9%
- Typical daily move
- ±4.9%
- Typical 20-day move
- ±9.7%
- 50-day average
- $37.53
- 200-day average
- $32.46
- Next earnings
- Nov 9
- Shares outstanding
- 78.53M
Celldex Therapeutics swing-trade checklist
Celldex Therapeutics scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $29.43 sits between the 50-day ($37.53) and 200-day ($32.46) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
69.4, Accumulation
Reading 69.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
32.1% below
Price is 32.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Nov 9, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−1.8% on average
From this point in the calendar, the next 20 trading days averaged −1.8% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Celldex Therapeutics stock chart and price history
Celldex Therapeutics closed at $29.43 on Oct 12, 2026, +6.9% over the past year, inside a 52-week range of $22.10 to $45.14.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −20.2%
- 3 months
- −22.9%
- 6 months
- −9.7%
- 1 year
- +6.9%
The full CLDX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CLDX in Gekko
Follow Celldex Therapeutics through every session
Put CLDX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CLDX in GekkoFree for 7 days. No credit card required.
About Celldex Therapeutics
Celldex Therapeutics works on antibody-based medicines, building monoclonal and bispecific antibodies meant to treat inflammatory illnesses and cancers. Its research includes a Phase I antibody that blocks the KIT receptor tyrosine kinase, an agonist antibody aimed at CD40 to stir immune activity against tumors, and a bispecific candidate combining PD-L1 blockade with CD27 costimulation to encourage T-cell responses against cancer.
The company develops its programs partly through outside collaborations and licensing arrangements. It has worked with the University of Southampton on human antibodies directed at CD27, with Amgen on rights tied to CDX-301 and CD40 ligand, and with Yale University.
Celldex Therapeutics was incorporated in 1983 and is based in Hampton, New Jersey. Its shares are listed on the NASDAQ under the ticker CLDX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- celldex.com
Celldex Therapeutics GekkoIndex: the smart money zone
Celldex Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 69.4, in the Accumulation zone, up 1.8 points over five sessions.
69.4Accumulation
Up 1.8 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 45 | +0.9% | +10.1% | ||
| Accumulation (current zone) | 252 | +0.3% | +3.3% | ||
| Neutral | 357 | 0.0% | −1.3% | ||
| Distribution | 24 | −2.0% | −11.5% | ||
| Selling | 4 | Too few readings yet | |||
Average CLDX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the CLDX price, zone by zone.Track CLDX in Gekko
Is Celldex Therapeutics stock overvalued? Gekko Fair Value
Celldex Therapeutics trades 32.1% below Gekko Fair Value of $43.35, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Celldex Therapeutics shares are worth, recalculated every trading day.
$43.35
Gekko Fair Value, Oct 10, 2026
32.1% Undervalued
At the end of Aug 2026 the price was 22.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open CLDX in Gekko
Celldex Therapeutics insider and Congress trading
No open-market insider purchases were filed for Celldex Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CLDX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CLDX, plotted on the chart in Gekko.Open CLDX in Gekko
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold CLDX.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Celldex Therapeutics earnings: next date and track record
Celldex Therapeutics reports on Nov 9, 2026 (28 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 9, 2026
28 days away
- EPS estimate
- −$1.02
- Revenue estimate
- $723K
5 of 8reports beat the EPS estimate
±4.8%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 2, 2026 | −$1.22 est −$1.00 | — | −3.8% |
| Nov 10, 2025 | −$1.01 est −$0.88 | — est $1.53M | +6.4% |
| Aug 7, 2025 | −$0.85 est −$0.86 | $730K est $1.18M | −3.6% |
| May 5, 2025 | −$0.81 est −$0.69 | $695K est $1.12M | −10.9% |
| Feb 24, 2025 | −$0.71 est −$0.71 | $1.18M est $1.25M | −7.4% |
| Oct 31, 2024 | −$0.64 est −$0.67 | — | −2.5% |
| Aug 8, 2024 | −$0.54 est −$0.59 | $2.50M est $820K | +2.7% |
| May 6, 2024 | −$0.56 est −$0.69 | $156K est $920K | −0.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Celldex Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Celldex Therapeutics is $63.07, +114.3% from the last close, from 12 firms rating the stock in the last 90 days.
$63.07consensus 12-month target, +114.3% from the last close
Now $29.43Avg $63.07
Low $28High $100
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | H.C. Wainwright | $64 | +117.5% |
| Oct 5 | Goldman Sachs | $28 | −4.9% |
| Oct 3 | LifeSci Capital | $64 | +117.5% |
| Oct 2 | H.C. Wainwright | $64 | +117.5% |
| Sep 28 | LifeSci Capital | $64 | +117.5% |
+3.3%average 20-day move after past Accumulation readings
−1.8%average move over the next 20 trading days in the last 5 years
±4.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Celldex Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Celldex Therapeutics averaged −1.8% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.3% | 2 of 5 |
| Next 10 trading days | −3.0% | 1 of 5 |
| Next 15 trading days | −4.0% | 1 of 5 |
| Next 20 trading days | −1.8% | 2 of 5 |
| Next 30 trading days | −3.4% | 1 of 5 |
For scale, CLDX’s typical 20-trading-day move in either direction is about 9.7%.
Celldex Therapeutics market cap and key statistics
Celldex Therapeutics’s market cap is $1.96B and revenue of $158K over the last twelve months.
Valuation
- Market cap
- $1.96B
- EPS, TTM
- −$4.35
- Gekko Fair Value
- $43.35
Trading
- Volume
- 596,401
- Avg volume, 20 days
- 2.35M
- 52-week high
- $45.14
- 52-week low
- $22.10
- Shares outstanding
- 78.53M
Financials
- Revenue, TTM
- $158K
- Profit margin
- 0%
- Return on equity
- -43.9%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.90
- Typical daily move
- ±4.9%
- Typical 20-day move
- ±9.7%
Celldex Therapeutics stock news this week
Coverage of Celldex Therapeutics this week reads neutral: 2 positive, 3 neutral and 0 negative headlines.
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)PRNewsWire, Oct 12
- Celldex Therapeutics Inc (TCE2.MU) Analyst insights, Price targets and RecommendationsYahoo Finance UK, Oct 8
- FMR LLC and Abigail P. Johnson Reveal 10.7% Stake in Celldex Therapeutics Inc.Kalkine Media, Oct 7
- An investment firm reports a passive stake of 8.4 million shares in Celldex Therapeutics (CLDX).Stock Titan, Oct 7
- Celldex reports Phase 3 success as HC Wainwright rates Celldex Therapeutics stock BuyAD HOC NEWS, Oct 7
- Celldex Therapeutics stock reports strong Phase 3 trial resultsAD HOC NEWS, Oct 5
Celldex Therapeutics peers
Celldex Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Celldex Therapeutics stock FAQ
What is Celldex Therapeutics’s market cap?
Celldex Therapeutics’s market cap is $1.96B at the Oct 12, 2026 close of $29.43, with 78.53M shares outstanding.
What is the Celldex Therapeutics stock forecast?
The consensus analyst 12-month price target for Celldex Therapeutics is $63.07, +114.3% from the last close. Of the 12 firms that rated the stock in the last 90 days, 11 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Celldex Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Celldex Therapeutics is undervalued: the Oct 12, 2026 close of $29.43 is 32.1% below Gekko Fair Value of $43.35. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Celldex Therapeutics report earnings next?
Celldex Therapeutics is expected to report on Nov 9, 2026 (28 days away). Analysts expect earnings of −$1.02 per share on revenue of $723K. Celldex Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 4.8% on average across the report.
What is Celldex Therapeutics’s 52-week high and low?
Celldex Therapeutics’s 52-week high is $45.14 and its 52-week low is $22.10; it closed at $29.43 on Oct 12, 2026, +6.9% over the past year. Over the last five years the shares peaked at $53.18 on Mar 4, 2024.
Is Celldex Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Celldex Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.